All In Biotech

Drug Trial Radar · NCT06760637

Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

AN INTERVENTIONAL, OPEN-LABEL, RANDOMIZED, MULTICENTER PHASE 3 STUDY OF PF-07220060 PLUS LETROZOLE COMPARED TO CDK4/6 INHIBITOR PLUS LETROZOLE IN PARTICIPANTS OVER 18 YEARS OF AGE WITH HORMONE RECEPTOR (HR)-POSITIVE, HER2-NEGATIVE ADVANCED/METASTATIC BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTICANCER TREATMENT FOR ADVANCED/METASTATIC DISEASE (FOURLIGHT-3)

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,037 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,037

Actual

Start

Jan 6, 2025

Primary completion

Jan 2, 2029

Study completion Dec 29, 2037

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jan 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety and efficacy of PF-07220060 with letrozole compared to approved treatments (ie, palbociclib, ribociclib or abemaciclib with letrozole) in people with breast cancer: * HR-positive (breast cancer cells that need estrogen or progesterone to grow) * HER2-negative (cells that have a small amount or none of a protein called HER2 on their surface); * locally advanced (that has spread from where it started to nearby tissue or lymph nodes) or metastatic disease (the spread of cancer to other places in the body) * who have not received any prior systemic anti-cancer treatment for advanced/metastatic disease. Approximately half of the participants will receive PF-07220060 plus letrozole while the other half of participants will receive the investigator's choice of treatment plus letrozole. The study team will monitor how each participant is doing with the study treatment during regular visits at the study clinic.

Conditions

  • Breast Cancer

Interventions

  • PF-07220060Drug

    CDK4 inhibitor

  • letrozoleDrug

    endocrine therapy

  • abemaciclibDrug

    CDK4/6 inhibitor

  • palbociclibDrug

    CDK4/6 inhibitor

  • ribociclibDrug

    CDK4/6 inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS) by BICRTime frame: From the date of randomization until disease progression or death due to any cause (up to approximately 4 years)

Locations

460 sites in 30 countries. Site status is shown where the registry gives one.

  • Infusion Therapy Extended Care Clinic (ECC)

    Birmingham, Alabama

  • The Kirklin Clinic of UAB Hospital

    Birmingham, Alabama

  • The University of Alabama at Birmingham

    Birmingham, Alabama

  • Ironwood Cancer & Research Centers

    Chandler, Arizona

  • Ironwood Cancer & Research Centers

    Gilbert, Arizona

  • Ironwood Cancer & Research Centers

    Glendale, Arizona

  • Ironwood Cancer & Research Centers

    Goodyear, Arizona

  • Ironwood Cancer & Research Centers

    Mesa, Arizona

  • Ironwood Cancer & Research Centers

    Mesa, Arizona

  • Ironwood Cancer & Research Centers

    Phoenix, Arizona

  • Ironwood Cancer & Research Centers

    Scottsdale, Arizona

  • CARTI Cancer Center Saline County

    Bryant, Arkansas

  • CARTI Cancer Center Conway

    Conway, Arkansas

  • Highlands Oncology Group, PA

    Fayetteville, Arkansas

  • CARTI Cancer Center

    Little Rock, Arkansas

  • CARTI Cancer Center North Little Rock Urology

    North Little Rock, Arkansas

  • CARTI Cancer Center North Little Rock

    North Little Rock, Arkansas

  • CARTI Cancer Center Pine Bluff

    Pine Bluff, Arkansas

  • Highlands Oncology Group, PA

    Rogers, Arkansas

  • Highlands Oncology Group, PA

    Springdale, Arkansas

  • Sutter Auburn Faith Hospital

    Auburn, California

  • Sutter Health Alta Bates

    Berkeley, California

  • Cedars-Sinai Cancer Beverly Hills (drug treatment and dispensing location)

    Beverly Hills, California

  • Cedars-Sinai Cancer Beverly Hills

    Beverly Hills, California

  • Marshall Cancer Center

    Cameron Park, California

  • Enloe Medical Center

    Chico, California

  • Enloe Regional Cancer Center

    Chico, California

  • City of Hope Investigational Drug Service (IDS)

    Duarte, California

  • City of Hope(City of Hope National Medical Center,City of Hope Medical Center)

    Duarte, California

  • UCSF Washington Hospital Cancer Center/ Washington Hospital Healthcare System

    Fremont, California

  • Premier Cancer Care and Infusion Center - Fresno - North Thesta Street

    Fresno, California

  • Providence Medical Foundation

    Fullerton, California

  • Providence St. Jude Medical Center Virginia K Crosson Cancer Center & Infusion Center

    Fullerton, California

  • City of Hope - Seacliff

    Huntington Beach, California

  • City of Hope at Irvine Lennar

    Irvine, California

  • City of Hope Investigational Drug Service (IDS)

    Irvine, California

  • Hoag Health Center Irvine

    Irvine, California

  • Hoag Hospital Irvine

    Irvine, California

  • City of Hope-Antelope Valley

    Lancaster, California

  • City of Hope at Long Beach Elm

    Long Beach, California

Showing 40 of 460 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.